CN116098256A - 茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用 - Google Patents
茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用 Download PDFInfo
- Publication number
- CN116098256A CN116098256A CN202310059903.6A CN202310059903A CN116098256A CN 116098256 A CN116098256 A CN 116098256A CN 202310059903 A CN202310059903 A CN 202310059903A CN 116098256 A CN116098256 A CN 116098256A
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- tea beverage
- beverage composition
- plaque
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013616 tea Nutrition 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 21
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 229930186217 Glycolipid Natural products 0.000 title claims abstract description 17
- 230000004060 metabolic process Effects 0.000 title claims abstract description 17
- 230000002792 vascular Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title description 7
- 244000124209 Crocus sativus Species 0.000 claims abstract description 22
- 235000015655 Crocus sativus Nutrition 0.000 claims abstract description 22
- 235000013974 saffron Nutrition 0.000 claims abstract description 21
- 239000004248 saffron Substances 0.000 claims abstract description 21
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 10
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 10
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 10
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 9
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 7
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 7
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 7
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 7
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 6
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 78
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 235000011194 food seasoning agent Nutrition 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000009849 vacuum degassing Methods 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 37
- 235000013305 food Nutrition 0.000 abstract description 6
- 244000269722 Thea sinensis Species 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 49
- 210000004369 blood Anatomy 0.000 description 45
- 239000008280 blood Substances 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 230000001603 reducing effect Effects 0.000 description 18
- 241001122767 Theaceae Species 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 235000013361 beverage Nutrition 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 10
- 208000026435 phlegm Diseases 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000011160 research Methods 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000000087 stabilizing effect Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical group C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 5
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 5
- 229960005370 atorvastatin Drugs 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 4
- 229960002327 chloral hydrate Drugs 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 101150037123 APOE gene Proteins 0.000 description 3
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 210000000702 aorta abdominal Anatomy 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000007213 cerebrovascular event Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 244000241838 Lycium barbarum Species 0.000 description 2
- 235000015459 Lycium barbarum Nutrition 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 210000002376 aorta thoracic Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 235000018927 edible plant Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000006371 metabolic abnormality Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000723353 Chrysanthemum Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000014493 Crataegus Nutrition 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 241000657480 Crataegus pinnatifida Species 0.000 description 1
- 235000004237 Crocus Nutrition 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000001031 immunopharmacological effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229910001112 rose gold Inorganic materials 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000010383 shanzha Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Tea And Coffee (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于食品领域,提供了一种茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用;所述茶饮组合物由如下原料制备而成:藏红花0.1‑0.5重量份,山楂10‑15重量份,枸杞子10‑15重量份,菊花10‑15重量份,陈皮10‑15重量份,红景天10‑15重量份。本发明提供的茶饮组合物可调节糖脂代谢,稳定并减少动脉粥样硬化斑块,保护血管弹性,并且方便购买,服用便捷。
Description
本申请是申请日为2019年12月20日、申请号为201911321891.X、发明名称为《一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物》的分案申请。
技术领域
本发明属于食品领域,具体涉及茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用。
背景技术
动脉粥样硬化(atherosclerosis,AS)是大、中动脉管壁出现增厚、变硬,最后导致血管壁弹性变差和管腔缩小等一系列退行性病变以及增生性病变的统称,容易引起组织缺血性改变,造成严重后果,是当今严重危害人类健康和生命的常见疾病。动脉粥样硬化斑块的稳定性与心脑血管事件的发生密切相关,易损斑块的破裂是急性脑梗死、急性心肌梗死等心脑血管危急重症较为常见且重要的原因。因此,稳定斑块,保护血管弹性是防止动脉粥样硬化引发心脑血管事件的重中之重。现代医学研究证明,服用他汀类药物是治疗动脉粥硬化,稳定易损斑块的主要治疗手段。他汀类药物通过不依赖于其降脂主导特性的抗炎作用来稳定斑块,从而减少急性心脏事件,在冠心病患者的一级和二级临床预防方面发挥着重要作用。与此同时,他汀类药物的安全性问题也一直备受关注,最常见的问题是血清转氨酶升高。可导致患者肝功能恶化的问题,因而部分患者不适宜或拒绝接受此类治疗方案。因此,急需在中医药领域寻找新的有效方药,发挥中医药干预治疗AS的临床优势,为患者提供可替代的临床选择,为减少心血管临床事件发生提供潜在的治疗手段和措施。
随着对AS研究的深入,抗AS药物也不断更新。中药是祖国的特有资源,常用于治疗许多西医难治之症,且疗效显著,它不仅价格低廉,还具备作用温和、不良反应小、不易残留、免疫药理调节作用明显等优势。陈月宁等用半夏白术汤预防性治疗患者颈动脉粥样硬化危险因素的发生和代谢异常效果良好。范如宇等通过临床研究和动物实验证明中药对易损斑块有较好的稳定作用。张红霞等发现用中药治疗AS家兔模型,可使家兔肝脏TG、TC、MDA含量降低,而SOD活性增强。舒士敏等研究发现配合清热解毒中药治疗冠心病能更好降低CRP和WBC水平,稳定斑块、降低患者心血管不良事件发生率。
中医药认为AS为本虚标实之证,本虚即五脏气血阴阳亏虚,标实即痰、瘀、热、毒等病理因素。血液中浊气伏于脉中,积聚日久为瘀、为痰,久病致虚所引起。所以在治疗上,临床医家大都采用祛瘀化痰,益气活血等治疗方法。
临床上认为痰瘀互结为AS的基本病机,针对痰瘀互结的根本病机。黄敬东通过采用辛伐他汀基础上加用降浊祛瘀汤治疗颈动脉粥样硬化患者80例,疗程为2个月。结果显示较之采用辛伐他汀口服的对照组,治疗组全血黏度、血浆黏度明显低于对照组,差异有统计学意义(P<0.05)。王志强等以化痰通络汤100例颈动脉粥样硬化斑块的干预,疗程6个月。结果提示,较之以基础治疗的对照组,治疗组消退斑块、减小斑块体积的效果明显优于对照组,组间比较差异显著(P<0.01);且治疗组发生脑血管事件和再住院病例数均减少,显著少于常规治疗组(P<0.05)。随着中医药事业的不断发展,发现中医药在治疗AS具有毒副作用小、经济实惠的优势,具有可靠的远期疗效。因此发挥中医药干预治疗AS的临床优势,可为患者提供可替代的临床选择。
中医自古以来就提倡且重视未病先防,早在《内经》中就提出了“治未病”的思想,强调“防患于未然”。现代医学模式也已转变为:健康应做到有病早治,无病早防,讲究合理营养,自我保健。中药保健饮料较早以药酒的形式出现,又称“酒剂”,在我国已有数千年的历史,其种类繁多,仅祛风散寒除湿类药酒就有几百种,目前中药保健饮料研制有茶、果汁饮料、固体饮料、奶制品、乳制品等种类,以前3种居多。
配方饮料具有饮用方便,相对体积(或重量)小,易保存运输,购买方便,不含有害物质等优点;目前研制出的中药保健功能主要定位在提高机体免疫、清心、降血糖、明目、润喉、清凉消暑等方面,如张英用22味中药经醇提浓缩成一定比例,配以其他辅料,精制而成具有固本培元,强壮身体,调节人体机体平衡,提高人体免疫力、抗疲劳、抗衰老等功效的长寿长乐饮。冯彦博以麦冬、人参须、甘草、竹叶为主要原料研制的具有清心增力功能的纯中药保健饮料。罗天顺等以高麦芽糖浆为主要甜味剂,加上适量高甜度的甜菊糖,配制出了含治疗性中药处方和不含中药处方系列的2类可乐风味饮料。前者为专供治疗糖尿病的饮料,后者可供一般人饮用,但该保健饮料尤其适用于糖尿病、高血压、高血脂和肥胖人群。
作为一种新发展的商品,配方饮料在许多国家和地区快速发展并流行,归因于它是一种健康的饮品,具有方便、卫生、快捷、口感好的优点。因此,中药配方饮料有着广阔的前景,是预防疾病,未病先防的良好选择。
发明内容
为了解决上述问题,本发明提供一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物,该茶饮组合物可调节糖脂代谢,稳定并减少动脉粥样硬化斑块,保护血管弹性。
本发明的另一目的在于提供一种上述茶饮组合物的制备方法。
为了实现上述目的,本发明提供一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物,由如下原料制备而成:藏红花0.1-0.5重量份,山楂10-15重量份,枸杞子10-15重量份,菊花10-15重量份,陈皮10-15g,红景天10-15重量份。
本发明还提供上述调节糖脂代谢消除斑块保护血管弹性的茶饮组合物的制备方法,包括如下步骤:
1)按配方重量称取藏红花,山楂,枸杞子,菊花,陈皮和红景天;
2)将山楂、枸杞子、陈皮和红景天混合,加上述4味药混合后质量和的8倍质量的纯化水煎煮1.5h,在煎煮结束前10min加入菊花和藏红花,继续煎煮10min,过滤分离得滤液和药渣;
由于花类药材含有较多的挥发油成分,不宜与其他药物共同放入,第一次煎煮结束前10分钟放入有利于发挥其药效,避免过多的破坏菊花和藏红花的有效成分。
3)将药渣再加入6味药质量和的8倍质量的纯化水煎煮1h,过滤得二次滤液和二次药渣;
4)将步骤2)制得的滤液和步骤3)制得的二次滤液合并;
5)调味、真空脱气、灌装、封口、杀菌、冷却、包装。
本发明提供的藏红花又名西红花、番红花,属名贵传统滋补品。藏红花原产于西班牙、希腊、南欧各国以及伊朗等地,世界80%的藏红花都产自伊朗。印度、日本也有栽培,经印度传入我国西藏,因而称为藏红花,在我国的西藏、浙江、江苏、山东、北京等地有栽培。作为药用植物藏红花在国外的最早记载是在公元1550年左右《埃伯斯纸草书》之中。藏红花是名贵中药材,以雌蕊的花柱及柱头入药,具有活血通经、解郁安神、养血祛淤、消肿止痛和凉血解毒等特效。藏红花还大量用于日化、食品、染料等行业,享有三个世界之最最贵的药用植物、最好的染料、最高档的香料,被西班牙人誉为“红色金子”。上海崇明从上世纪80年代初开始种植藏红花,是中国最大的藏红花种植地,其中90%的藏红花产于此地。传统医药古籍记载藏红花具有活血化瘀、凉血解毒、解郁安神之功效,可用于经闭癥瘕、产后瘀阻、温毒发斑、忧郁痞闷、惊悸发狂等症。现代药理学研究表明,藏红花具有强身健体的功效。越来越多的研究证实,藏红花具有治疗心血管疾病、动脉粥样硬化、高脂血症、精神类疾病、神经退行性疾病、学习记忆障碍、糖尿病、高血压、胃溃疡、脂肪肝以及抗癫痫、抗惊厥等多种活性。
山楂又名山里红,味酸微温,具有消食健胃和行气散瘀的功能。主要用于肉食积滞,胃脘胀满,泻痢腹痛,瘀血经闭,产后瘀阻,心腹刺痛,高血脂等症,并有增加胃液分泌而促进消化的作用。近代医学发现,山楂能调节心肌功能,降低血液中胆固醇和血脂在血管壁上的沉积,改善心肌糖的代谢,有降血压、降血脂、软化血管、强心、抑菌、增加冠脉流量、抗心率不齐的作用。
红景天味甘、苦,性平,归肺、心经,具有益气活血、通脉平喘的功效,具有保护心脏、抗疲劳、抗心肌缺血、抗辐射、抗癌、抗糖尿病、调节神经系统等作用。山楂、红景天两者皆可配合藏红花起到活血化瘀通脉的功效。
陈皮始载于《神农本草经》,列为上品,主胸中瘾热,逆气,利水谷,久服去臭下气;味苦、辛,性温,具有理气健脾,燥湿化痰功效,主治胸脘胀满,食少吐泻,咳嗽痰多,是一味常用中药,也是药食两用佳品,在肝、肺、心脑血管系统、呼吸及消化系统疾病中均发挥着积极作用。陈皮理气,可助藏红花、红景天益气活血,又可健脾化痰,与山楂共同起到消积滞、化痰浊的作用。
菊花性微寒,味甘苦,具有散风清热、平肝明目、清热解毒的作用,《本草纲目》中记载,菊花能利五脉,调四肢,治头风热补,同时现代药理学研究表明,菊花具有改善心肌营养、去除活性氧自由基、加强毛细血管的抵抗力,降低血液中脂肪和胆固醇的含量、抑制肿瘤、延缓衰老及增强人体免疫力等功效。菊花与山楂两者均具有一定的调脂作用,可通过调脂对动脉粥样硬化斑块的稳定或减小起到一定的功效。
枸杞子味甘、性平,归肝、肾经,有滋补肝肾、益精明目之功效,用于虚劳精亏、腰膝酸痛、眩晕耳鸣、内热消渴、血虚萎黄、目眩不明等病症,现代药理学研究表明枸杞子具有抗氧化、抗衰老、神经保护、抗阿尔茨海默病和保肝明目等药理活性,并且可以提高机体的非特异性免疫功能。枸杞子性味平和,其补益作用可配合以上活血化瘀通脉药,以防活血太过而致的耗气伤血。
本发明所提供的山楂、陈皮、枸杞子均为药食同源植物,营养价值丰富,藏红花、菊花及红景天为茶饮常用药,临床应用价值高,六味药物补泻结合,共奏调节糖脂代谢、稳定并减小动脉粥样硬化斑块、保护血管弹性的功效,组合而成功能饮料,适合长期服用。
本发明的有益效果在于:
本发明提供一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物及其制备方法,该茶饮组合物可调节糖脂代谢,稳定并减少动脉粥样硬化斑块,保护血管弹性,并且方便制备和购买,服用便捷。
附图说明
图1为本发明所提供茶饮组合物对总胆固醇影响的实验结果统计图;
图2为本发明所提供茶饮组合物对甘油三酯的影响的实验结果统计图;
图3为本发明所提供茶饮组合物对HDL-C的影响的实验结果统计图;
图4为本发明所提供茶饮组合物对LDL-C的影响的实验结果统计图;
图5为本发明所提供茶饮组合物对各组小鼠主动脉斑块HE染色结果图(X40);
图6为本发明所提供茶饮组合物对各组小鼠主动脉根部的冰冻切片油红O染色结果图(X40),其中,箭头所示油红O染成红色部位为AS斑块;
图7为本发明所提供茶饮组合物对脉搏传导速度的影响结果图。
具体实施方式
下面将对本发明的实施例进行详细、完善的描述,以使本发明的优点和特征能更易于被本领域技术人员理解,从而对本发明的保护范围做出更为清楚明确的界定。
实施例1
本发明提供一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物,具体由藏红花2g,山楂120g,枸杞子120g,菊花120g,陈皮120g,红景天120g组成。
制备过程为:
1)按配方重量称取藏红花,山楂,枸杞子,菊花,陈皮和红景天;
2)将山楂、枸杞子、陈皮和红景天混合,加上述4味药混合后质量和的8倍质量的纯化水煎煮1.5h,在煎煮结束前10min加入菊花和藏红花,继续煎煮10min,过滤分离得滤液和药渣;煎煮方式为文火煎煮,保持微沸。
3)将药渣再加入6味药质量和的8倍质量的纯化水煎煮1h,过滤得二次滤液和二次药渣;煎煮方式为文火煎煮,保持微沸
4)将步骤2)制得的滤液和步骤3)制得的二次滤液合并,浓缩。
浓缩比例为:将滤液浓缩至2710ml,取出387ml即为低浓度(0.2g/ml),继续浓缩至1161ml,取出387ml即为中浓度(0.4g/ml),继续浓缩至387ml即为高浓度(0.8g/ml)。
实施例2
茶饮组合物的疗效
实验动物:SPF级Apoe-/-雄性小鼠42只,C57Bl/6雄性小鼠10只,体重18g-22g,周龄:8周。两种小鼠均购自北京维通利华公司。Apoe-/-小鼠为C57BL/6野生型小鼠经载脂蛋白E基因剔除后得到的小鼠,表现出异常高血脂症状,可通过饲喂高脂饲料建立动脉粥样硬化模型。Apoe-/-雄性小鼠实际使用40只,C57Bl/6雄性小鼠实际使用8只,各余2只作为备用预防饲养期死亡。
环境温度为(24±1)℃,湿度为(55±5)%,普通饲料适应性喂养3天,自由饮水,SPF级饲养,打耳标编号。将C57Bl/6雄性小鼠8只为对照组,Apoe-/-雄性小鼠随机分为模型组、阿托伐他汀组(西药组)、中药高、中、低(浓度)剂量组,每组各8只。
实验药材:
1.将实施例1制备的茶饮组合物浓缩成生药浓度为0.2g/mL、0.4g/mL、0.8g/mL的低、中、高3个浓度剂量组,以对应小鼠分组;根据小鼠与人体体表面积单位换算,灌胃剂量为10mL/kg。
2.阿托伐他汀钙片:规格:10mg,由北京嘉林药业股份有限公司生产。
3.普通饲料:含51%碳水化合物、16%蛋白质、4%维生素和矿物质、3%脂肪,由西苑医院动物实验中心提供。
4.高脂饲料:41%脂肪,43%碳水化合物,17%蛋白质,由北京华阜康公司提供。
喂养方法,给药方式、剂量及时间:1.空白对照组,给予基础饲料喂养,同时每天灌胃生理盐水一次,灌胃量胃0.1ml/10g,灌胃时间为8周。2.模型组,阿托伐他汀对照组,中药高、中、低浓度剂量组,均给予高脂饲料喂养。3.模型组同时给予生理盐水灌胃,灌胃量为0.1ml/10g。灌胃时间为8周。4.阿托伐他汀对照组同时给予阿托伐他汀片水溶液灌胃,灌胃量为0.1ml/10g;灌胃时间为8周。5.中药高、中、低浓度剂量组给予中药浓煎水溶液灌胃,灌胃量为0.1ml/10g;灌胃时间为8周。
1、对血脂的影响
灌胃实验结束后,将小鼠禁食12h,眼底静脉丛取血,血样于室温静置2h,5000r/min离心10min后,取上层血清置于-80℃贮存。TC、TG、LDL-C、HDL-C水平均严格按照总胆固醇(TC)试剂盒、甘油三酯(TG)试剂盒、低密度脂蛋白胆固醇(LDL-C)试剂盒、高密度脂蛋白胆固醇(HDL-C)试剂盒(上述试剂盒均购自富士胶片和光纯耀(上海)化学有限公司)的相关说明测定,每个样品重复测2次,取平均值。
结果如表1所示:
表1各组小鼠血脂四项水平比较
1.1对总胆固醇的影响
根据表1对总胆固醇(TC)统计结果作图,如图1所示。
从图1可以看出,与模型组比较,西药组与中药中浓度剂量组总胆固醇明显降低,差异有统计学意义(P<0.05),中药低浓度剂量组及中药高浓度剂量组与模型组的差异无统计学意义(P>0.05)。说明中药中浓度剂量组对高脂饮食诱导的动脉粥样硬化小鼠有降低胆固醇的作用,推测与中药浓度有关。
1.2对甘油三酯的影响
根据表1对甘油三酯(TG)统计结果作图,如图2所示。
从图2可以看出,与模型组比较,中药低浓度剂量组甘油三酯水平明显降低,差异有统计学意义(P<0.05),西药组、中药高浓度剂量组及中药低浓度剂量组与模型组的差异无统计学意义(P>0.05);与西药组比较,中药低剂量组的差异有统计学意义。从上述结果可以看出,中药低浓度剂量组对小鼠甘油三酯疗效明显
1.3对HDL-C的影响
根据表1对高密度脂蛋白胆固醇(HDL-C)统计结果作图,如图3所示。
从图3可以看出,与模型组比较,中药中浓度剂量组高密度脂蛋白水平明显降低,差异有统计学意义(P<0.05),西药组、中药高浓度剂量组及中药低浓度剂量组与模型组的差异无统计学意义(P>0.05);与西药组比较,中药中浓度剂量组及中药低浓度剂量组高密度脂蛋白水平明显降低,差异有统计学意义(P<0.05),中药高浓度剂量组的差异无统计学意义(P>0.05)。实验结果提示,中药中浓度剂量对小鼠的高密度脂蛋白胆固醇有降低作用。
1.4对LDL-C的影响
根据表1对低密度脂蛋白胆固醇(LDL-C)统计结果作图,如图4所示。
从图4可以看出,与模型组比较,西药组及中药高、中、低浓度剂量组差异均无统计学意义(P>0.05)。实验结果提示中药组对于小鼠低密度脂蛋白胆固醇无明显的调节作用。
从上述结果可以看出,对于茶饮组合物的中低浓度对于调节血脂中总胆固醇、甘油三酯、高密度脂蛋白胆固醇的降低有效,而高浓度则对于血脂指标没有明显效果,推测是由于浓度过高影响小鼠吸收。
2对斑块面积的影响
2.1各组小鼠AS斑块HE染色结果(X40)
实验小鼠于末次给药后禁食12h,10%水合氯醛(30mL·kg-1)腹腔麻醉。小鼠处死,游离胸主动脉到腹主动脉末端,取出整段血管,经无RNA酶的磷酸缓冲液洗涤后,一部分血管组织经10%甲醛固定,石蜡包埋、切片,蒸馏水漂洗2min,苏木精染色液染色5min,自来水冲洗30s,洗去多余染液,1%盐酸酒精分化5s,返蓝15min,伊红染色液染色90s,梯度脱水,二甲苯透明,中性树胶封片后显微镜下观察拍照。从图5可以看出,正常小鼠的主动脉管腔完整光滑,动脉壁内膜、中膜形态正常,各层结构清晰(图5中A)。模型组的管腔明显变窄,内膜明显增厚,弹力纤维断裂溶解,内含大量泡沫细胞及炎症细胞,中膜平滑肌细胞排列紊乱(图5中B)。与模型组比较,阿托伐他汀组的主动脉斑块面积较小,动脉内膜比较光滑,平滑肌细胞及胶原纤维成分较多,斑块内有大小不等的泡沫细胞堆积,斑块趋于稳定(图5中C)。中药给药组主动脉斑块面积较小,内皮较模型组完整,中膜平滑肌细胞增殖,排列尚规则,见图5中D至F。说明中药组能够减小斑块面积,对AS有明显抑制作用。
2.2各组小鼠主动脉根部的冰冻切片油红O染色结果(X40)
实验小鼠于末次给药后禁食12h,10%水合氯醛(30mL·kg-1)腹腔麻醉。小鼠处死,游离胸主动脉到腹主动脉末端,取出整段血管,经无RNA酶的磷酸缓冲液洗涤后,取部分主动脉根部组织,OCT包埋后液氮速冻10-20s,待组织块冷冻后,用冰冻切片机切片,切片置于常温中干燥20min后,100%异丙醇孵育5min,置于0.5%油红O染液中染色7-8min,再用85%异丙醇孵育3min,水洗后,苏木精染液复染2min,流水冲洗返蓝,甘油明胶封片,显微镜下观察拍照。
从图6可以看出,与正常组比较,模型组小鼠主动脉根部有明显的AS形成,油红O染色后脂质呈鲜红色。与模型组比较,各给药组被油红O染成鲜红色的区域显著减少,即斑块面积减少。说明中药组可减少血管内脂质沉积,从而对AS具有抑制作用。
3对血糖的影响
实验动物:SPF级雌性大鼠40只,7周龄,体质量200~220g,北京维通利华实验动物技术有限公司提供。实验动物饲养于中国中医科学院西苑医院基础医学研究所动物室,饲以大鼠标准颗粒饲料,自由饮水。
实验药材:
1)将实施例1制备的茶饮组合物浓缩成生药浓度为0.8g/mL,根据大鼠与人体体表面积单位换算,灌胃剂量为10mL/kg。
2)奥氮平,由上海源叶生物技术有限公司提供。
3)普通饲料:含51%碳水化合物、16%蛋白质、4%维生素和矿物质、3%脂肪,由西苑医院动物实验中心提供
大鼠适应性喂养1周,称重,随机分为3组,分别为空白组(C组)、模型组(M组)、中药组(T组),每组8只。模型组与中药组于晚上黑暗时相前1h给予奥氮平1.2mg/kg(pH 5.2柠檬酸-柠檬酸钠缓冲液)灌胃,次日上午分别给予等体积蒸馏水及中药配方灌胃;空白组于晚上黑暗时相前1h灌胃等体积柠檬酸-柠檬酸钠缓冲液,次日上午给予等体积蒸馏水,连续给药4周。
取材:末次给药当晚大鼠禁食不禁水,次日上午空腹以7%水合氯醛腹腔注射麻醉后,腹主动脉取血,5000r/min离心10min,取上清用于检测,结果如表2所示。
表2各组大鼠血糖水平比较
组别 | GLU(mmol/L) |
空白组(C组) | 6.81±1.32 |
模型组(M组) | 8.92±1.65* |
中药组(T组) | 6.99±1.87 |
从表2可以看出,中药组与空白组比较,差异有统计学意义;中药组与模型组比较,差异有统计学意义。从上述结果可以看出,中药组可有效改善大鼠血糖水平。
4对脉搏传导速度的影响
将前述的实验小鼠末次给药前,10%水合氯醛(30mL·kg-1)腹腔麻醉。待小鼠麻醉后,对小鼠胸腹部进行脱毛、备皮,充分暴露胸腹部。采用Vevo2100型动物超声仪器,探头选用L40-8/12(频率20MHz)。找到小鼠主动脉,进行PWV数据采集,保持不动采集5s,通过管壁的运动描记脉搏波波形,计算PWV值,采用SPSS22.0统计学软件进行分析。
从图7可以看出,中药各浓度剂量组与模型组比较,差异有统计学意义。中药组对于小鼠的血管弹性具有改善保护作用。
由上述实验结果可知,本发明提供的茶饮组合物对于动物动脉粥样硬化斑块有一定的减小作用,可以改善血脂状况,尤其对降低总胆固醇有明显的作用,以及调节血糖水平,保护血管弹性等作用。
1、本茶饮组合物在基于长期临床疗效的基础之上,通过动物实验验证了其调节血糖的疗效,以及调节血脂的疗效,尤以胆固醇为主,通过主动脉油红染色及HE染色涂片可明确观察到本茶饮组合物的减小动脉粥样硬化斑块的疗效,通过对脉搏传导速度结果的比较,可知在使用本茶饮组合物的情况下,脉搏传导速度较慢,血管弹性尚可。
2、六味药物组方简单,却配伍合理,补泻结合,相辅相成,能够起到调节糖脂代谢,稳定并减小动脉粥样硬化斑块,保护血管弹性等多种功效。六位药物中既具有药食同源植物,又包含茶饮常用药物,安全性上具有极大的保障。且该配方口感较好,适于动脉粥样硬化斑块形成的病人以及动脉粥样硬化高危人群如腹型肥胖、糖脂代谢异常等代谢综合征人群长期服用。
3、当前社会经济水平逐渐提高,人们的生活方式、饮食结构也随之发生变化。工作压力、不良的饮食结构及生活习惯致使越来越多的人出现代谢综合征,成为动脉粥样硬化高危人群,如腹型肥胖、糖脂代谢异常等,而相当一部分人群直至出现动脉粥样硬化斑块问题才选择就诊,甚至对此忽视,或是因为拒绝长期服用西药而放弃治疗。该六味药物组方配伍的稳定并减小动脉粥样硬化斑块、保护血管弹性、为代谢综合征等高危人群提供预防方法的配方茶目前市场空缺,以便捷的服用方法及较好的口感起到预防及治疗动脉粥样硬化问题的功效。
最后说明的是,以上优选实施例仅用于说明本发明的技术方案而非限制,尽管通过上述优选实施例已经对本发明进行了详细的描述,但本领域技术人员应当理解,可以在形式上和细节上对其作出各种各样的改变,而不偏离本发明权利要求书所限定的范围。
Claims (4)
1.茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用,其特征在于,所述茶饮组合物由如下原料制备而成:藏红花0.1-0.5重量份,山楂10-15重量份,枸杞子10-15重量份,菊花10-15重量份,陈皮10-15重量份,红景天10-15重量份。
2.根据权利要求1所述的应用,其特征在于,所述茶饮组合物由如下原料制备而成:藏红花0.2重量份,山楂12重量份,枸杞子12重量份,菊花12重量份,陈皮12重量份,红景天12重量份。
3.根据权利要求1或2所述的应用,其特征在于,所述的茶饮组合物的制备方法,包括如下步骤:
1)按配方重量称取藏红花,山楂,枸杞子,菊花,陈皮和红景天;
2)将山楂、枸杞子、陈皮和红景天混合,加上述4味药混合后质量和的8倍质量的纯化水煎煮1.5h,在煎煮结束前10min加入菊花和藏红花,继续煎煮10min,过滤分离得滤液和药渣;
3)将药渣再加入6味药质量和的8倍质量的纯化水煎煮1h,过滤得二次滤液和二次药渣;
4)将步骤2)制得的滤液和步骤3)制得的二次滤液合并;
5)调味、真空脱气、灌装、封口、杀菌、冷却、包装。
4.根据权利要求3所述的应用,其特征在于,步骤2)和步骤3)所述煎煮是用文火煎煮,保持微沸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310059903.6A CN116098256A (zh) | 2019-12-20 | 2019-12-20 | 茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310059903.6A CN116098256A (zh) | 2019-12-20 | 2019-12-20 | 茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用 |
CN201911321891.XA CN111011558A (zh) | 2019-12-20 | 2019-12-20 | 一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911321891.XA Division CN111011558A (zh) | 2019-12-20 | 2019-12-20 | 一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116098256A true CN116098256A (zh) | 2023-05-12 |
Family
ID=70212317
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911321891.XA Pending CN111011558A (zh) | 2019-12-20 | 2019-12-20 | 一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物 |
CN202310059903.6A Pending CN116098256A (zh) | 2019-12-20 | 2019-12-20 | 茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911321891.XA Pending CN111011558A (zh) | 2019-12-20 | 2019-12-20 | 一种调节糖脂代谢消除斑块保护血管弹性的茶饮组合物 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN111011558A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104491186A (zh) * | 2015-01-06 | 2015-04-08 | 北京市中医研究所 | 一种抗动脉粥样硬化的药物及其制备方法 |
CN105267431A (zh) * | 2015-09-30 | 2016-01-27 | 李文 | 一种具有即饮特点的,有降血脂作用的中药保健品组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1408283A (zh) * | 2001-09-22 | 2003-04-09 | 马永军 | 红花茶 |
CN104621296B (zh) * | 2013-11-11 | 2017-10-10 | 南京拓鉒医药科技有限公司 | 一种具有调节血脂、血糖、血压功能的中药组合茶饮料 |
CN108524673A (zh) * | 2018-07-16 | 2018-09-14 | 北京和通世嘉投资管理有限责任公司 | 一种中药组合物及其应用 |
-
2019
- 2019-12-20 CN CN201911321891.XA patent/CN111011558A/zh active Pending
- 2019-12-20 CN CN202310059903.6A patent/CN116098256A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104491186A (zh) * | 2015-01-06 | 2015-04-08 | 北京市中医研究所 | 一种抗动脉粥样硬化的药物及其制备方法 |
CN105267431A (zh) * | 2015-09-30 | 2016-01-27 | 李文 | 一种具有即饮特点的,有降血脂作用的中药保健品组合物 |
Non-Patent Citations (3)
Title |
---|
孔增科: "《常用中药药理与临床应用》", vol. 1, 31 January 2005, 内蒙古科学技术出版社, pages: 386 * |
李卉: "《高血压饮食调养速查轻图典》", vol. 1, 31 January 2014, 江西科学技术出版社, pages: 117 * |
赵学萍: "中藏药结合治疗高脂血症40例临床研究"", 《河北中医》, vol. 33, no. 4, 30 April 2011 (2011-04-30), pages 527 - 528 * |
Also Published As
Publication number | Publication date |
---|---|
CN111011558A (zh) | 2020-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105112265A (zh) | 一种保健无花果酒及其制作方法 | |
CN111919934A (zh) | 一种用于降三高保护心血管的红花苏心茶及其制备方法 | |
CN101543295B (zh) | 一种降压降脂保健茶 | |
GB2589967A (en) | Chinese yellow rice wine containing ingredients of mulberry leaves (morus alba L.) and silkworm pupae (bombyx mori) and production method thereof | |
CN108524673A (zh) | 一种中药组合物及其应用 | |
CN102318830B (zh) | 一种降脂减肥食品及其制备工艺 | |
CN104293552A (zh) | 一种减肥葡萄酒 | |
CN105029553A (zh) | 一种果汁蛋钙中药保健饮料及其制备方法 | |
CN1504560A (zh) | 一种仙人掌酒及其制备方法 | |
CN104450470A (zh) | 一种柘果保健酒及其制备方法 | |
CN108969591A (zh) | 一种净化血液的制剂 | |
CN111135235A (zh) | 一种预防和缓解急性酒精中毒或醉酒的组合物 | |
CN102120951B (zh) | 一种灵芝浓缩液、灵芝酒及生产方法 | |
CN109820123A (zh) | 一种改善微循环的植物饮品及其制备方法 | |
CN104435648A (zh) | 一种食药两用的组合物及其用途和制备方法 | |
CN116098256A (zh) | 茶饮组合物在制备调节糖脂代谢、消除斑块和保护血管弹性产品中的应用 | |
CN111870630A (zh) | 一种用于增加抵抗力和免疫力的药物配方及制备工艺 | |
CN106234699A (zh) | 一种清热宣化治疗发热的药茶及制备加工方法 | |
CN109757633A (zh) | 一种枸杞玫瑰功能饮料及其制备方法 | |
CN110669623A (zh) | 一种菊花养生酒及其制备方法 | |
CN109362925A (zh) | 一种养颜花茶蜜及其制备方法 | |
CN108004090A (zh) | 一种保健药酒及其制备方法 | |
NL2037306B1 (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof | |
CN110755523B (zh) | 一种改善高血糖的组合物及其制备方法 | |
CN116688002A (zh) | 一种降四高的养生保健茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |